Aclaris Therapeutics, Inc. (ACRS) Is At $22.83 Formed Wedge; China North East Petroleum Holdings LTD (NEP) Sentiment Is 0.92

NextEra Energy Partners, LP acquires, owns, and operates contracted clean energy projects. The company has market cap of $2.24 billion. It owns interests in wind and solar projects in North America, as well as in seven contracted natural gas pipeline assets in Texas. It has a 32.97 P/E ratio. It has a portfolio of approximately 2,926 megawatts of renewable energy projects.

Aclaris Therapeutics, Inc. (ACRS) formed wedge down with $21.92 target or 4.00% below today’s $22.83 share price. Aclaris Therapeutics, Inc. (ACRS) has $703.96M valuation. The stock increased 0.09% or $0.02 during the last trading session, reaching $22.83. About 332,812 shares traded. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has risen 25.57% since December 24, 2016 and is uptrending. It has outperformed by 8.87% the S&P500.

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics has $54 highest and $20 lowest target. $40.80’s average target is 78.71% above currents $22.83 stock price. Aclaris Therapeutics had 14 analyst reports since November 2, 2015 according to SRatingsIntel. The stock has “Outperform” rating by William Blair on Monday, November 2. Jefferies maintained the shares of ACRS in report on Friday, August 12 with “Buy” rating. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has “Buy” rating given on Monday, November 2 by Citigroup. Jefferies maintained the shares of ACRS in report on Monday, June 26 with “Buy” rating. JMP Securities initiated the shares of ACRS in report on Friday, September 30 with “Market Perform” rating. The firm has “Outperform” rating given on Tuesday, November 29 by Leerink Swann. The rating was initiated by Jefferies on Monday, November 2 with “Buy”. Guggenheim initiated the shares of ACRS in report on Friday, June 10 with “Buy” rating. The firm has “Buy” rating given on Wednesday, August 9 by Cantor Fitzgerald. Jefferies maintained Aclaris Therapeutics, Inc. (NASDAQ:ACRS) on Thursday, August 31 with “Buy” rating.

Analysts await Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report earnings on March, 21. They expect $-0.90 earnings per share, down 83.67% or $0.41 from last year’s $-0.49 per share. After $-0.63 actual earnings per share reported by Aclaris Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 42.86% negative EPS growth.

The stock decreased 0.29% or $0.12 during the last trading session, reaching $41.34. About 233,192 shares traded. NextEra Energy Partners, LP (NEP) has risen 18.85% since December 24, 2016 and is uptrending. It has outperformed by 2.15% the S&P500.

Analysts await NextEra Energy Partners, LP (NYSE:NEP) to report earnings on January, 26. They expect $0.27 EPS, down 70.33% or $0.64 from last year’s $0.91 per share. NEP’s profit will be $14.65 million for 38.28 P/E if the $0.27 EPS becomes a reality. After $0.01 actual EPS reported by NextEra Energy Partners, LP for the previous quarter, Wall Street now forecasts 2,600.00% EPS growth.